We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmaceutical company, Lupin Ltd on Wednesday posted a two fold increase in net profit at Rs 50.19 crore for the quarter ended March 31 as against Rs 21.73 crore for the same quarter during the year 2004-05.
Carna Biosciences, Inc. and Enamine Ltd. jointly announced the signing of a collaboration agreement to cooperate on discovery and development of lead compounds against targeted kinase.
Pliva, Eastern Europe's biggest drug maker by sales, saw its profits take a massive dive in the first quarter of 2006, as a huge loss of royalties could not be offset by the relatively small growth in its generics business.
Sponsors of clinical trials in South Africa should provide special medical insurance to compensate participants if they suffer adverse effects, according to South African Health Minister Manto Tshabalala-Msimang.
Japan-based Eisai has reported that its UK subsidiary Eisai Ltd. has filed an application for the Alzheimer's treatment Aricpet (donepezil HC1 tablet) with the Medicines and Healthcare Products Regulatory Agency of the UK.
India-based Shantha Biotechnics is progressing with its plans to introduce DTP+ Hep B+ Hib pentavalent vaccine -- which protects against diphtheria-tetanus-pertussis, hepatitis B and haemophilus influenza type B -- by the end of 2006.
Accentia Biopharmaceuticals, Inc., on May 15, 2006, entered into definitive purchase agreements in a private placement of its common stock and warrants led by institutional investors totaling $8,235,000.
Epigenomics AG, a molecular diagnostics company developing tests based on DNA methylation, announced today that the company has entered into an agreement to continue a collaboration with AstraZeneca Ltd. to identify and analyse potential DNA methylation biomarker candidates for use in AstraZeneca's oncology programs.
Shares of Neurocrine Biosciences Inc. took a premarket nosedive Tuesday after the Food and Drug Administration refused to approve the highest dose of the biotech company's insomnia drug candidate.